Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. - Wikidata - wikimedia - TriplyDB

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.

http://www.wikidata.org/entity/Q38390044

about

Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Liquid biopsy genotyping in lung cancer: ready for clinical utility?Interventional pulmonology approaches in the diagnosis and treatment of early stage non small cell lung cancer Circulating tumor DNA detection in lung cancer patients before and after surgery Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.A genetic interaction analysis identifies cancer drivers that modify EGFR dependency.Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors.Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer.Personalized therapy for lung cancer: Striking a moving target

P2860

Q28077504-BBB10F72-205E-4F00-9EAC-E0CA5436B53D Q28603408-C25D7AEB-73B9-4BEA-BBEE-346DBD170D30 Q33567037-42781AC6-BA6A-4765-9C86-4C000B013771 Q35200670-F2A9CE40-6B42-4B01-B610-C64DAA5E8F73 Q37264643-3A5B01E1-D01F-437F-A29F-5C65AAD11359 Q37339704-3BE560D5-36F7-4BBC-B89D-0609B562519D Q37353957-DE85C275-2D86-47CD-9882-4B3DD99178AD Q38390205-6B2E22B2-C844-4E22-ABC4-F95DBF99CC1F Q38717620-147DF3F1-EE02-45F0-8978-774C323F155B Q41603225-9354FC83-33BB-450F-BAAF-0CA323FA845D Q47116265-703EF655-E006-463B-BB62-A5DF41DC6E98 Q52904961-550683FB-D1DA-43CA-B6E4-0044972EA2C8 Q58792324-68C856F5-142A-4902-907C-58FA2BB7EDE4

P2860

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.

http://www.wikidata.org/entity/Q38390044

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Tumor heterogeneity: evolution ...... all cell lung cancer patients.

@en

type

label

Tumor heterogeneity: evolution ...... all cell lung cancer patients.

@en

prefLabel

Tumor heterogeneity: evolution ...... all cell lung cancer patients.

@en

P1433

Q38390044-1DCED009-1550-40D4-A655-A94B79F0D6F7

P1476

Q38390044-F3951C6E-BE9C-4F2A-A803-3C5BC2D6705E

P2093

Q38390044-3F12DFF2-4007-4428-9461-21693BE1FDFB

Q38390044-9228980C-AB70-4105-B370-FCD1D8742202

P2860

Q38390044-013EB307-3FF3-48BC-86E2-5BA7C085E58C

Q38390044-0244122E-C709-4971-931C-E1C5451199DB

Q38390044-053A3543-E055-4182-AE85-CFB220B50D28

Q38390044-07F6B918-28C7-4AB2-8607-D18D29641B9E

Q38390044-082C5CBE-A9A9-4092-BC16-BC445E693A46

Q38390044-08DDDE66-5481-4CB8-B62B-59E947C4A5EA

Q38390044-0A3AA556-B59C-49E1-9A11-2D3146A49931

Q38390044-0CB76C8D-F150-4E57-B79C-D10C9ADF91E7

Q38390044-118BF9BB-9FCC-4BBA-9952-050D46ADC7AD

Q38390044-14226296-68C9-494E-AD2C-E8A970664E08

P304

Q38390044-5F5AF2CD-7056-47DE-B652-F2B4EE7D0730

P31

Q38390044-9151944E-79B0-42CA-A987-928212940DD3

P356

Q38390044-A9D4D539-D3A5-46CD-B3A9-8EB3C2DD10EE

P433

Q38390044-5DC26D9D-8005-417E-BC1E-BC5785C82DC4

P478

Q38390044-1E643D6E-9E6E-483A-A320-AE5E39D36B19

P577

Q38390044-BF772891-4305-4F0A-8537-E0B4D48B81F8

P698

Q38390044-50251BA5-50AB-4B1D-BD79-31CF225F0B15

P932

Q38390044-F5479435-282E-44EA-ACC9-297A2101B50E

P356

J.ISSN.2218-6751.2013.03.09

P1433

Translational lung cancer research

P1476

Tumor heterogeneity: evolution ...... all cell lung cancer patients.

@en

P2093

Jordi Remon

http://www.w3.org/2001/XMLSchema#string

Margarita Majem

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

226-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2218-6751.2013.03.09

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25806236

http://www.w3.org/2001/XMLSchema#string

P932

4367601

http://www.w3.org/2001/XMLSchema#string